A Phase 1/2, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

This study is testing a new experimental cancer medication called ISM3412 to see how safe it is and how well it works in people with advanced solid tumors. The goal is to find the best dose of this new treatment to help patients whose cancer has spread and hasn't responded to standard therapies.

This trial is for adults 18 or older who have solid tumors that cannot be removed by surgery and contain a specific genetic change called an MTAP deletion. Participants must be well enough to perform daily activities and have exhausted or not tolerated other available treatment options.

You will receive the experimental medication ISM3412 while your doctors carefully monitor your health and any side effects. The study involves two parts: first finding the right dose, and then confirming how well that dose works, with regular check-ups and medical scans to track your tumor.

This study is currently recruiting patients at medical centers in Denver, Colorado; New Haven, Connecticut; and Indianapolis, Indiana. You can talk to your doctor to see if one of these locations is convenient for you.